EGFR and lung adenocarcinoma: When performing driver mutation testing in patients with lung adenocarcinoma, it is preferable to use next‐generation sequencing (NGS), which can detect a broad spectrum of mutations, including EGFR L861R, rather than a single‐plex EGFR assay.